Peter Gottlieb, MD

Professor of Pediatrics and Medicine, Barbara Davis Center, University of Colorado School of Medicine

---

Peter Gottlieb, MD is a physician-scientist and internationally recognized leader in type 1 diabetes clinical and translational research, with more than two decades of experience advancing immune-based therapeutic development and disease-modifying strategies. His work focuses on the immune mechanisms underlying type 1 diabetes and other autoimmune diseases, with particular emphasis on antigen-specific T cells and B cells, and he has authored more than 190 peer-reviewed publications.

He is a Professor at the Barbara Davis Center at the University of Colorado School of Medicine, where he holds the Orr Family Endowed Chair in Adult Diabetes. Dr. Gottlieb has played a leading role in advancing clinical trial development in type 1 diabetes through his long-standing involvement with the Type 1 Diabetes TrialNet program. A member since its inception, he has served as Chair of the Collaborative Mechanistic Studies Panel and as a clinical investigator on numerous intervention trials spanning prediabetes (Stages 1 and 2) and clinical diabetes (Stage 3), in collaboration with TrialNet, the Immune Tolerance Network, and industry partners.

Dr. Gottlieb received his M.D. from Rutgers Medical School and completed his residency in Internal Medicine and fellowship in Endocrinology at the University of Massachusetts Medical School. He subsequently completed postdoctoral training in Immunology at the Weizmann Institute in Rehovot, Israel and currently serves as a strategic consultant to the T1D Fund.